TrialJAMA oncology2021

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

Caicun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.